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Abstract
Human immunodeficiency virus type 1 (HIV-1) is a rapidly evolving pathogen and
causes the acquired immunodeficiency syndrome (AIDS) in humans. There are ~30-35
million people infected with HIV around the world, and ~25 million have died since the first
reported cases in 1981. Additionally, each year 2-3 million people become newly infected
and more than one million die of AIDS. An HIV-1 vaccine would help halt an AIDS
pandemic, and efforts to develop a vaccine have focused on targeting the HIV-1 envelope,
Env, found on the surface of the virus. A number of chronically infected individuals have
been shown to produce antibodies, called broadly neutralizing antibodies (bnAbs), that
target many strains of HIV-1 by binding to Env, thus suggesting promise for HIV-1 vaccine
development. BnAbs to take years to develop and have a number of traits that inhibit their
production; thus, a number of researchers are trying to understand the pathways that
result in bnAb production so that they can be elicited more rapidly by vaccination. This
review discusses results and implications from two HIV-1 infected individuals studied
longitudinally who produced bnAbs against two different sites on HIV-1 Env, and
immunization studies that used Envs deriving from those individuals.
Keywords:
HIV-1, Env, immunogen, epitope, conformation, co-evolution, heterologous neutralization
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Introduction
HIV-1, the etiological agent of AIDS, is a rapidly evolving pathogen. The complex
nature of the HIV envelope, Env, has impeded the development of an effective HIV-1
vaccine.1 Env is a trimeric gp160 assembly that is processed into gp120 (CD4 receptorbinding subunit (CD4bs)) and gp41 (transmembrane subunit) by furin cleavage.2 Gp120
sometimes is “shed”, leaving behind gp41 “stumps”, or other oligomers, which are
incapable of cell entry3 and can favor the production of strain-specific, or non-neutralizing,
antibodies.4, 5 An added level of humoral immune evasion stems from the dynamic nature
of HIV Env and conformational masking.6-12 Upon binding to the host cell receptor CD4,
gp120 undergoes large conformational changes to an “open” state that permits
subsequent binding of a co-receptor, triggering further conformational changes and
ultimately host-cell entry mediated by gp41 rearrangements.13 These different
conformations of Env present immunodominant epitopes, misdirecting the humoral
immune response to produce non-protective antibodies.
HIV also evades the immune system by rapid mutation14, particularly within the five
variable loops (V1-V5)15, and extensive glycosylation16-18, of Env. V1–V3 are found at the
apex of the trimer (Fig. 1), and are important for trimer association and cell entry.19, 20 V5
is found near the CD4 binding site. Env glycosylation, which can be quite heterogeneous
because of steric effects against glycan processing enzymes21, 22, serves to shield a large
portion of gp120 since carbohydrate moieties may appear as “self” to the immune system.
HIV-1 broadly neutralizing antibodies (bnAbs), which target >50% viral variants, are
produced in up to 25% of infected individuals23-26, suggesting promise for HIV-1 vaccine
development27. The epitopes of currently identified bnAbs cluster on six predominant
immunogenic regions on Env28, 29. Moreover, bnAbs develop over a course of at least 4-5
years of infection. It is now possible to obtain longitudinal virus and antibody sequences
from HIV-infected donors because of improvements in single B-cell sorting technologies30,
single-genome amplification and sequencing31 and computational approaches that allow
the inference of progenitor antibodies32(Fig. 2). These data allow the investigation of virusantibody co-evolutionary pathways through the development of bnAbs33-35,13,14 to provide
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pathways.36
A number of structural analyses have been performed on HIV-1 bnAb-producing
donors studied longitudinally33-35, 37, 38, but Envs from only two of those cases have been
tested in animals (Fig. 2). In this review, we will discuss the two longitudinal cases and the
related immunization studies. We will focus on lessons learned from the infected donors,
structural features of the immunogens used, and considerations for future studies.
HIV-Antibody “Arms Race” Analyses for B-cell Immunogen Design Approaches
Infection with an HIV transmitted founder (T/F) virus31 causes the immune system
to produce strain-specific antibodies against the T/F Env.39 The virus “escapes” recognition
by mutating its Env rapidly. Processes of somatic hypermutation (SHM) and recombination
in B-cells results in antibodies with a greater affinity for escape virus Envs40, which then
mutate to yield new escape virus Envs.41 Because they mutate rapidly, most circulating
viruses are resistant to antibodies from the same time point. These co-evolutionary
trajectories produce a virus-antibody “arms race”, which in some cases results in
antibodies that can target heterologous tier-2 (difficult to neutralize) viruses42, 43 and
bnAbs.
Understanding the patterns of antibody affinity maturation resulting in bnAb
development could lead to the design of immunogens that increase the likelihood of
maturation along the desired, yet disfavored, pathways leading to bnAbs36, 44, 45. A
vaccination protocol based on a B-cell lineage would prime with one immunogen, and
boost with a sequence of several different immunogens.46 To do this, one would design
immunogens with an enhanced affinity for the unmutated common ancestor (UCA)47 and
intermediate antibodies using their paratopes as structural templates. This relies on
available structural information – ideally, crystal structures would be determined of the
complex of the mature antibody Fab with antigen, and of the UCA and one or more
intermediate antibodies. A structure of a UCA–antigen or intermediate antibody–antigen
complex would also be helpful, but the native antigen may not bind tightly enough to the
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determine how to target the UCA.
CH505: CD4bs bnAb development
The CH103 Broadly Neutralizing Antibody Lineage
Liao et al.38 tracked the co-evolution of the CH103 CD4bs bnAb lineage and the
clade C CH505 HIV-1 Env isolated from an African patient, CH505, starting approximately 4
weeks after infection through the development of bnAbs. Interestingly, all CH103 lineage
members, even the UCA, could bind the T/F virus Env. Mutations in the autologous CH505
virus Env did, however, escape recognition by earlier members of the antibody clonal
lineage. Moreover, as antibody maturation proceeded, the more mature members of the
lineage could bind with increasing affinity to heterologous virus Envs.
The crystal structure of the complex formed between the bnAb CH103 Fab
fragment and a gp120 outer domain showed that CH103 interacted with the gp120 CD4binding loop, V5 loop, and D loop38. The interaction was dominated by the heavy chain
complementarity determining region (CDR) 3 loop of CH103, which interacts with the
CD4bs. The UCA CDRH3 loop was more flexible than that of more mature members, which
likely explains its lack of breadth. To understand affinity maturation, unliganded Fab
structures were analyzed by superposing heavy-chain variable domains (VH) on that of
CH103 because the VH domain contacts the conserved CD4 binding loop.48 The
superposition showed that during affinity maturation, the orientation of the light-chain
variable domain (VL) shifted with respect to VH, likely to accommodate gp120 V5 loop
insertions that occurred during the first year of infection, and which would relieve
unfavorable contacts with the UCA light chain. The shift was observed between
intermediate antibodies I3 and I2, which corresponded to the point at which heterologous
neutralization occurred. Thus, the shift in orientation could account for the ability of
CH103 bnAbs to bind heterologous Envs with larger V5 loops.
Results from these studies suggested that binding for a T/F Env to a UCA B-cell
receptor (BCR) of a bnAb lineage like CH103 can induce bnAbs and be used as a potential
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antibodies occurred between the UCA and I3, and between I3 and I2, Envs that bind I3 and
I2 should be used as boosts to trigger I3- and I2-like antibodies to drive forward a CH103like lineage. This bnAb lineage is an especially promising lineage to attempt to mimic via
sequential vaccination because its natural evolution required fewer mutations compared
to other CD4bs bnAbs to become broad.
The CH235 Cooperating Lineage
Viruses typically mutate to escape immune pressures, but CH103 was observed to
bind Envs with D-loop mutations more avidly. Why the virus mutated to become more
sensitive to CH103-lineage antibodies turned out to be the consequence of a
“cooperating” antibody lineage, called CH235, another bnAb lineage produced in the
CH505 donor.49, 50 The CH235 and CH103 lineages demonstrated cooperative evolution
throughout the course of HIV-1 infection: the virus developed an escape mutation in
response to the CH235 lineage, which drove forward the development of the CH103 bnAb
lineage. A hallmark of this cooperative evolution is that both antibodies interact at the
same site on Env to drive their development.
Unlike CH103, the VH domain of the CH235 lineage antibodies mimicked CD4
binding to gp120.51, 52 Additionally, unlike CH103, CH235 had very few interactions with
the V5 loop, but had significant interactions with the D loop49. To compensate for escape
D-loop mutations, the antibody strengthened its binding to the C4 region, which is on the
opposite face of gp120. Negative stain EM 3D reconstructions showed that CH235
members bound to a closed Env trimer with an approach angle similar to that of VRC0153
and other CD4-mimicking bnAbs.
Studies from the CH505 donor suggest that an immunization strategy could use the
CH505 T/F Env to induce naive B-cell responses. The presence of cooperating lineages
suggests that a strategy for simultaneous induction of CDRH3 and VRC01-class CD4bs
bnAbs as elicited here, could be to follow up by sequential immunizations using D loop
mutant Envs.
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CH505 Immunization Studies
Williams et al.54 studied the development of HIV-1 targeted antibodies induced by
vaccination using four CH505 Envs as gp120s: the T/F Env and Envs from weeks 53, 78, and
100. Sequential immunizations of rhesus macaques (RMs) with the four gp120s in their
natural order produced the DH522 antibody clonal lineage. This lineage was the most
similar to that of CH103, but only had autologous tier-1 (neutralization-sensitive),
heterologous tier-1 and weak heterologous tier-2 neutralization activities.42 A crystal
structure of the DH522.2 Fab in complex with a gp120 core, together with a superposition
on the BG505 Env SOSIP.664 (gp140) trimer revealed that the antibody bound to the
CD4bs in a way that the antibody would clash with a nearby gp120 subunit.54 A negative
stain EM 3D reconstruction showed that the antibody bound to an open conformation of
the Env trimer. The inability to bind the closed trimer explains the limited neutralization
breadth of these clonal lineage members, and suggests that future immunizations should
use closed trimers, such as disulfide stabilized SOSIPs.29, 55
In another CH505 immunization study Saunders et al.56 vaccinated rabbits with
CH505 T/F chimeric SOSIP trimers containing a BG505 gp41 region to help stabilize the
closed Env conformation.18 Additional Env mutations were included to eliminate exposure
of V3 loop epitopes and co-receptor binding sites.57 Overall results were better when using
stabilized CH505 Envs versus non-stabilized ones.56 Rabbits receiving these stabilized Envs
produced autologous tier-2 neutralizing plasma. Deletion of CD4bs shielding glycans from
immunogens resulted in more CD4bs antibodies, including ones that could neutralize
heterologous tier-2 viruses. While the antibody epitope(s) were not determined, these
studies show the importance of Env stabilization in the induction of tier-2 neutralizing
antibodies. Moreover, since removing glycans from certain sites on Env could induce larger
antibody responses58, immunization strategies could use enlarged “glycan hole” Envs as
primes, and then boost with sequential Envs that have smaller “glycan holes” to
concentrate the antibody response towards a more desirable site. Some germline-targeted
trimer-based vaccine approaches have used this approach. For example, others have
focused on creating glycan holes and changing variable loop lengths and residues around a
particular epitope on the BG505 SOSIP trimer that was modified to target the germline of
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with successive trimers in which the native surface of Env was gradually restored resulted
in cross-reactive antibodies 59,60. These results suggest that similar results could be
achieved with suitable trimers based on lineage studies, such as from CH505.
Four CH505 Envs from similar time-points were also used in rhesus macaque
sequential immunization studies conducted by Saunders et al.56 In this case, cleavage
deficient forms of the gp140 trimer were used, since these were previously shown to be
immunogenic, and induced low levels of antibodies to certain tier-2 HIV-1 strains in guinea
pigs61 and in macaques62, 63. One macaque produced tier-2 HIV-1 neutralizing plasma, but
against the V1V2 region, even though CD4bs-targeting immunogens were used. These
results demonstrated that V1V2-directed antibodies are more readily induced than those
against the CD4bs. This is consistent with the fact that CH235.12 had a favorable
orientation in binding the CD4bs, but still needed high degrees of SHM (>20%) to develop
breadth49, 50. Studies done in knock-in mice suggest receptor editing and different antibody
gene usage in macaques versus humans could also inhibit CD4bs bnAbs development.54
Thus, it may be easier to induce bnAbs against other epitopes.
CH848: V3-glycan bnAb development
The DH270 Broadly Neutralizing Antibody Lineage
V3-glycan bnAbs penetrate the Env glycan “shield” and contact both carbohydrate
and protein components at the V3 loop base, which includes the highly conserved GDIR
motif64. These bnAbs require the glycan at N332 for binding and neutralization, and some
also require other glycans, such as the one at N301. Thus, members of this class of bnAbs
have different Env footprints65-68. For example, in contrast to other V3-glycan bnAbs,
DH270-lineage bnAbs have shorter CDRs but are still able to penetrate the glycan shield at
a different approach angle, as demonstrated by a negative stain EM 3D reconstruction37.
This binding diversity, together with the limited SHM required for bnAb development
against this site, suggests that this class of bnAbs may be easier to elicit by a vaccine.
To better understand V3-glycan bnAb development, the co-evolution of the DH270
bnAb lineage and the clade C CH848 HIV-1 Env isolated from an African patient, CH848,
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glycopeptide, which was designed based on the epitope of the V3-glycan bnAb PGT12867
and includes both N301 and N332 glycans. It was demonstrated that Man9-V3 structurally
mimics the V3 region of an intact trimer69 and binds to antibodies with a similar affinity as
gp120 or trimers69, suggesting its promise for studying antibody-Env interactions, and its
use as an immunogen. A similar peptide was used to isolate the DH270.6 bnAb and DH475
cooperating antibody (discussed later) from this patient37.
In contrast to the CH103 lineage, the DH270 UCA did not bind to the autologous
T/F virus Env.37 Heterologous breadth and potency of DH270 lineage antibodies increased
with the accumulation of VH mutations, with improbable mutations playing a critical role
in affinity maturation.31,59 Improbable mutations are rare events that occur at cold spot
microsequences71, 72 and once they occur, they are likely to remain fixed in a lineage.
Crystal structures of DH270.6 and DH270.3, which is less potent/broad, in complex with
Man9-V3 and the Man9 glycan, respectively, revealed that two low-probability mutations
were needed for specific anchoring at two complementary positions on Env and therefore
breadth.65 The G57RH mutation, which occurred early, allowed intermediate IA4 (or a
precursor) to latch onto the V3 loop backbone near the GDIR motif in a different manner
from other V3-glycan bnAbs35, 66, 67; the later R98TH mutation in the DH270.6 branch, and
absent in the DH270.3 branch, relieved the conserved D115H residue from a salt bridge
within the antibody, so it could bind a high mannose N332 glycan moiety, similar to what
was observed in other V3-glycan bnAbs35, 67. Thus, repeated immunization with modified
Envs to select for the improbable mutations, such as G57RH and R98TH, may be essential
for bnAb induction.
A challenge in initiating a similar lineage as DH270 by vaccination is the fact that its
UCA did not bind any sequenced Env trimers or free glycans. The DH270 UCA did, on the
other hand, bind to the Man9-V3 glycopeptide and its aglycone form (preferential binding
to the glycopeptide form increased throughout affinity maturation).37 One explanation for
this is that some altered form of CH848 T/F Env (such as a shed gp120 or fragment of it)
exposed the V3 loop that stimulated the germline BCR to produce this lineage. This
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the synthetic Man9-V3 glycopeptide, before boosting with an Env trimer.
The DH272 and DH475 Cooperating Lineages
DH270 bnAb lineage development was aided by two autologous neutralizing
cooperating lineages, DH272 and DH475, which also bind the V3-glycan region in an N332
glycan-dependent manner.37 DH272 and DH475 targeted viruses in the first year and
selected viral escape mutants that would become sensitive to DH270 bnAb lineage
members. After 51 weeks, a V1 loop deletion (34 to ~16 V1 loop residues) resulted in a
switch in neutralization sensitivity from the DH272 and DH475 lineages to the DH270
lineage. Due to the proximity of the V1 and V3 loops (Fig. 1)73, the V1 loop deletion could
either alter the conformation of V3, or minimize steric interference that longer V1 loops
present. There was a restoration of longer V1 loops later in infection and later DH270
antibodies adapted to viruses with longer V1 loops, similarly to other V3-glycan bnAbs,
allowing recognition of a broader spectrum of Envs and enhancing breadth.37
Exactly how DH475 and DH272 bind to Env to cause the escape mutations in V1 has
yet to be determined, which would guide immunogen design to engage similar responses.
The action of cooperating lineages for bnAb development suggests that immunogen
strategies will require multiple Envs and boosting regimens. These results specifically
suggest that a vaccine regimen should include boosts with Env trimers with progressive V1
lengths.
CH848-Related Immunization Studies
Alam et al.70 and others (unpublished data) are exploring the use of the Man9-V3
glycopeptide as an immunogen since it was found to interact with the DH270 UCA of
CH848. Not only would such a peptide mimic the bnAb epitope and bind a germline
antibody, but it will also minimally present dominant strain-specific epitopes74, suggesting
promise as an immunogen. Rhesus macaques were immunized with the Man9-V3
glycopeptide to test whether antibodies against the V3-glycan epitope could be induced.70
Three antibodies were isolated that could selectively bind Man9-V3 and not its aglycone
version. Two of these could also bind to CH848 T/F and consensus C gp120s, were sensitive
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data showed that Man9-V3 immunization could induce antibody responses against the V3glycan bnAb region.
While the monomeric Man9-V3 glycopeptide is not a potent immunogen, its
potency could be increased by multimerization of Man9-V3, such as mounting it on a
nanoparticle as was done for the engineered outer domain targeting B-cell precursors of
the VRC01 bnAb75 and for the short chain oligosaccharides for producing anti-glycan
antibodies against Streptococcal challenges. 76 Such multimerization would increase
multivalency to more effectively increase activation of the necessary B cell pools.
It still remains to be determined whether an immunization strategy that primes
with the Man9-V3 glycopeptide and boosts with trimers would be effective at producing
bnAbs. A recent study with fusion peptide immunizations followed by boosts with the
BG505 SOSIP trimer have yielded cross-clade neutralizing responses77, suggesting that a
similar approach with a V3 glycopeptide may yield promising results as well. The
antibodies isolated from rhesus macaque immunizations with Man9-V3 have not been
structurally determined in complex with the glycopeptide or Env, thus it is unknown yet
whether other considerations are needed when using Man9-V3. Additional structural
information would help guide such immunization studies.
Other Considerations
While the variability of the antibody repertoire among individuals could pose a
challenge for B-cell immunogen design, for some viral-neutralizing epitopes the relevant
immunoglobulin repertoire consists of a small number of VH families, suggesting that
different individuals may produce similar maturation pathways.78, 79 There have also been
examples of convergent evol-ution of human antibodies, in which antibodies with similar
gene usage can be isolated from different subjects80-83, or of antibodies that could arise
with similar CDR structures using different VH families84-88, lending support for longitudinal
studies in HIV vaccine development.
Moreover, much of the emphasis in the field has been on elucidating bnAb-Env
interactions89 and determining changes in antibody structure during affinity maturation.33-
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Affinity enhancing mutations in antibodies or virus escape mutations could alter
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thermostability or dynamics90-94, suggesting these features could also play a role in virusantibody co-evolution and should be considered in immunogen design strategies.
Moreover, there is also a lack of Env structures throughout virus evolution and
glycosylation patterns of T/F Envs may be different from the more difficult to neutralize
tier-2 and tier-3 Envs.42, 95, 96 Thus, structures of autologous virus Envs throughout their
evolution should be determined.
There is also evidence that truncating the Env gp41 tail, as is done for SOSIP
trimers, can alter the antigenicity of the trimer97, suggesting that use of a full length Env
may be necessary for structural studies and immunization trials. Together with the use of
nanodiscs98-100, which will provide a stabilizing environment for the transmembrane region
of Env, advances in cryo-electron microscopy101-104 and single molecule fluorescence
microscopy105 are likely to play important roles in structurally characterizing Envs and
providing insights for immunization trials.
Conclusions
A goal of HIV-1 immunogen design is to combine other bnAb specificities to achieve
a broad coverage of T/F viruses. Additional co-evolution studies, as the ones described
here, will help provide greater insights to achieve this goal. To account for both B-cell
ontogeny and co-evolution, it will be important to consider both the conformation of Env
and the “rate-determining” steps to induce bnAb development via prime-boost regimens.
Of note, it may not be ideal to study bnAb development in rhesus macaques using human
derived data, since rhesus macaques do not use the same antibody genes and since
immunization studies have not yet resulted in bnAbs 62, 106, 107. Exploring virus-antibody
co-evolution and performing immunization trials in the same model would help
circumvent this problem. An example of this would be to study infection in SHIVs108, and
follow up with immunization trials in rhesus macaques to determine if vaccination could
result in similar antibodies as those produced in SHIV infections.
While Env trimers may better mimic the trimer on an intact virion than a
monomeric gp120 and mask non-neutralizing epitopes, such trimers may not bind to the
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interact with the progenitor antibodies and mimic the natural epitope, like the Man9-V3
glycopeptide, could be used as a prime in such cases. Furthermore, such a synthetic
immunogen would be helpful in displaying an epitope that might otherwise be a
heterogeneous in the context of a trimer. Chemical synthesis can overcome this hurdle by
generating glycopeptides with homogeneous glycosylation patterns109. Moreover, such a
peptide could present the bnAb epitope without interference from other surface
features—e.g., the nearby gp120 V1V2 loop, which can interfere with V3 loop recognition.
The absence of distracting epitopes in Man9-V3 suggests that minimal antigens of this kind
might be suitable candidate immunogens in regimens involving long-term antigenic
exposure. To enhance viral clearance, it might be useful to use Man9-V3 in conjunction
with a monomer containing a T-cell helper epitope, such as a glycoconjugate of the nonnatural pan DR epitope110. Moreover, to improve immunogenicity, the peptide could be
conjugated to a ligand such as the Toll-like receptor 2 lipopeptide as was described
elsewhere for a V3-glycopeptide-based immunization study.111 Trimers may be used in
succession, especially if cooperating lineages recognizing other Env regions are necessary
for bnAb development. Trimers used in germline-targeted immunization approaches have
shown promise for inducing cross-reactive antibodies59,60 and thus should be considered in
lineage-based immunogen design efforts as well.
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Figure Legends
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Figure 1. HIV Env Structure. The receptor-binding gp120 (red) and the transmembrane

bound gp41 (green), which are targets for vaccine design, are shown as a surface diagram.

Variable loops (V1V2, V3, and V5) and the CD4bs are colored as indicated in the figure.
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Figure 2. Scheme of workflow for analyzing HIV-antibody arms races for immunogen
design purposes. HIV-1 infected donors are recruited and longitudinal sequences of HIV
and antibodies are determined using single B-cell sorting and Env gene amplification and
sequencing. Phylogenetic trees are constructed from available sequence data and
computational approaches, and then structural analysis is done to determine key
structural changes that might identify rate-limiting steps, important for immunogen
design. Immunogens are then introduced into vaccinated or infected individuals and the
process is repeated.

